Trader consensus prices "No" at 84% implied probability for a new WHO-designated COVID-19 variant of concern before 2027, driven by sustained high population immunity from vaccines and prior infections that have kept recent SARS-CoV-2 subvariants in check. The past week's wastewater data shows BA.3.2 ("Cicada"), a highly mutated Omicron descendant with immune escape potential, circulating in over 30 U.S. states and 33 countries since late March 2026, yet test positivity remains low at 3.4% with no surge in hospitalizations or deaths. ECDC and WHO track it as a variant under monitoring without VOC elevation—requiring clear evidence of heightened transmissibility, severity, or treatment failure—amid declining global genomic surveillance. A sharp rise in virulence could still prompt reclassification by year-end.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाहाँ
$233,739 वॉल्यूम
$233,739 वॉल्यूम
हाँ
$233,739 वॉल्यूम
$233,739 वॉल्यूम
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
बाज़ार खुला: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus prices "No" at 84% implied probability for a new WHO-designated COVID-19 variant of concern before 2027, driven by sustained high population immunity from vaccines and prior infections that have kept recent SARS-CoV-2 subvariants in check. The past week's wastewater data shows BA.3.2 ("Cicada"), a highly mutated Omicron descendant with immune escape potential, circulating in over 30 U.S. states and 33 countries since late March 2026, yet test positivity remains low at 3.4% with no surge in hospitalizations or deaths. ECDC and WHO track it as a variant under monitoring without VOC elevation—requiring clear evidence of heightened transmissibility, severity, or treatment failure—amid declining global genomic surveillance. A sharp rise in virulence could still prompt reclassification by year-end.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न